Iqbal Asif, Badoo Shoaib, Naqeeb Ruqsana
Department of Anaesthesiology and Critical Care, SMHS Hospital, GMC, Srinagar, Jammu and Kashmir, India.
Saudi J Anaesth. 2017 Apr-Jun;11(2):232-235. doi: 10.4103/1658-354X.203057.
Malignant hyperthermia is rare inherited disorder in our part of the world; there are only few cases reported in literature in India who were suspected of having this condition. The overall incidence of malignant hyperthermia during general anesthesia is estimated to range from 1: 5000 to 1: 50,000-100,000 and mortality rate is estimated to be <5% in the presence of standard care. In India, there is no center where halothane caffeine contraction test is performed to confirm diagnosis in suspected cases. Second, dantrolene drug of choice for this condition is not freely available in market in India and is stored only in some hospitals in few major cities. Among the cases reported of suspected of malignant hyperthermia in India almost 50% have survived the condition despite nonavailability of dantrolene emphasizing role of early detection and aggressive management in these cases.
恶性高热在我们这个地区是一种罕见的遗传性疾病；在印度，文献中仅报道了少数疑似患有这种疾病的病例。全身麻醉期间恶性高热的总体发病率估计在1:5000至1:50000 - 100000之间，在有标准治疗的情况下，死亡率估计低于5%。在印度，没有任何中心进行氟烷咖啡因收缩试验以确诊疑似病例。其次，治疗这种疾病的首选药物丹曲林在印度市场上无法自由获取，仅在少数大城市的一些医院有储备。在印度报道的疑似恶性高热病例中，尽管没有丹曲林，但几乎50%的患者存活了下来，这凸显了早期检测和积极治疗在这些病例中的作用。
